Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H M Prince

Showing results (91-100 of 151) with videos related to

Pageof 16
Sort By:
Arthritis Research & Therapy|March 21, 2012
Sustained rheumatoid arthritis remission is uncommon in clinical practiceFemke H M Prince, Vivian P Bykerk, Nancy A Shadick, et al.
Clinical and Experimental Immunology|September 17, 2013
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapyA C Chan, P Neeson, E Leeansyah, et al.
Bone Marrow Transplantation|June 3, 2014
Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trialK E Herbert, L Demosthenous, G Wiesner, et al.
Leukemia|November 7, 2008
Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparatorK E Herbert, S Morgan, H M Prince, et al.
Bone Marrow Transplantation|June 26, 2007
The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR studyS Feyler, H M Prince, R Pearce, et al.
Internal Medicine Journal|February 18, 2009
Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatmentM Dickinson, H M Prince, S Kirsa, et al.
Bone Marrow Transplantation|March 22, 2005
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantationA Spencer, N Horvath, J Gibson, et al.
Leukemia|October 22, 2010
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapyD A Carney, D A Westerman, C S Tam, et al.
Bone Marrow Transplantation|November 24, 2004
Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group StudyA Wirth, H M Prince, M Wolf, et al.
Arthritis Care & Research|October 10, 2012
Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritisSiri Lillegraven, Nina Paynter, Femke H M Prince, et al.
Pageof 16

Showing results (91-100 of 151) with videos related to

Sort By:
Pageof 16
Arthritis Research & Therapy|March 21, 2012
Sustained rheumatoid arthritis remission is uncommon in clinical practiceFemke H M Prince, Vivian P Bykerk, Nancy A Shadick, et al.
Clinical and Experimental Immunology|September 17, 2013
Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapyA C Chan, P Neeson, E Leeansyah, et al.
Bone Marrow Transplantation|June 3, 2014
Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trialK E Herbert, L Demosthenous, G Wiesner, et al.
Leukemia|November 7, 2008
Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparatorK E Herbert, S Morgan, H M Prince, et al.
Bone Marrow Transplantation|June 26, 2007
The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR studyS Feyler, H M Prince, R Pearce, et al.
Internal Medicine Journal|February 18, 2009
Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatmentM Dickinson, H M Prince, S Kirsa, et al.
Bone Marrow Transplantation|March 22, 2005
Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantationA Spencer, N Horvath, J Gibson, et al.
Leukemia|October 22, 2010
Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapyD A Carney, D A Westerman, C S Tam, et al.
Bone Marrow Transplantation|November 24, 2004
Optimal scheduling to reduce morbidity of involved field radiotherapy with transplantation for lymphomas: a prospective Australasian Leukaemia and Lymphoma Group StudyA Wirth, H M Prince, M Wolf, et al.
Arthritis Care & Research|October 10, 2012
Performance of matrix-based risk models for rapid radiographic progression in a cohort of patients with established rheumatoid arthritisSiri Lillegraven, Nina Paynter, Femke H M Prince, et al.
Pageof 16